VJHemOnc Podcast The AML Sessions: IDH inhibitors
Nov 3, 2020
Clinicians discuss the use of IDH inhibitors in acute myeloid leukemia (AML) and myelodysplastic syndromes, exploring combination therapies, patient selection challenges, and the potential impact of combining IDH inhibitors with chemotherapy on differentiation syndrome. Promising results have been observed in phase one and two studies, and further advancements and strategies in the field are anticipated.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 3min
Development and Study of IDH Inhibitors in AML
02:36 • 5min
Patient selection, mutation types, and challenges in trial interpretation
07:45 • 2min
IDH Inhibitors for Treatment of MDS and AML
09:40 • 11min
Combining IDH Inhibitors with Chemotherapy: Impact on Differentiation Syndrome
20:35 • 6min